Patent 11021495 was granted and assigned to Calithera Biosciences on June, 2021 by the United States Patent and Trademark Office.
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.